>
Organization
Sarepta Therapeutics, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on Sarepta Therapeutics, Inc.

... the growth of the market. Key Vendors Alnylam Pharmaceuticals Bausch Health Biogen Sarepta Therapeutics Topics Covered PART 03: MARKET LANDSCAPE PART 02: SCOPE OF THE ...
... begins a new chapter in its development, following the recent partnership with Sarepta. During his 30-year career in the pharmaceutical and biotech industries, Philippe spent ...
... CNS. A pivotal clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. and a phase 1-2 clinical trial in GM1 Gangliosidosis are in ...
... as Senior Vice President and Chief Commercial Officer of Cambridge, Massachusetts-based Sarepta Therapeutics, Inc. (Nasdaq:SRPT), a leader in precision genetic medicine for rare diseases. Mr. ...
... Exondys51 and Emflaza have not been approved for DMD treatment in Europe Sarepta, PTC, Santhera, Italfarmaco, and Catabasis are some of the key players operating ...
... (LGMD), in collaboration with Nationwide Children's Hospital's Center for Gene Therapy and Sarepta Therapeutics, announced today the initiation of a clinical trial evaluating MYO-101, a ...
... CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today ...
... CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today ...
... CAMBRIDGE - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, granted ...
Subscribe now for full coverage on Sarepta Therapeutics, Inc.
Start My Free Trial